Information Provided By:
Fly News Breaks for August 4, 2017
XLRN
Aug 4, 2017 | 05:47 EDT
Citi analyst Robyn Karnauskas raised her price target for Acceleron Pharma shares to $44 saying the Luspatercept expansion continues with another Phase 3 trial planned for early 2018. The analyst expects to see MRI-based muscle weight/ strength data at 150mg dosing by year-end 2017. She believes muscle could be the next big catalyst and keeps a Buy rating on Acceleron shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN